Results of Operations and Financial Condition. On August 4, 2026, Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchan…

Results of Operations and Financial Condition. On May 13, 2026, Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchang…

Class II director — Habib J. Dable: The company appointed a new director with significant industry experience.

principal accounting officer — Julia Rueb: Julia Rueb was promoted to principal accounting officer.

Other Events. On March 4, 2026, Tyra Biosciences, Inc. (the “Company”) agreed to issue and sell 4,000,000 shares of common stock to a large investment management firm at a purchase price of $31.50 per share. The Company expects to receive $126.0 million in gross proceeds upon settlement, before deducting fees and other expenses payable by it. The shares of common stock are being issued as a block transaction under the Company’s “at-the-market” offering program, which has been registered under…

Results of Operations and Financial Condition. On March 2, 2026, Tyra Biosciences, Inc. issued a press release announcing its financial results for the year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchan…

Chief Operating Officer — Bhavesh Ashar: Bhavesh Ashar was appointed as the Chief Operating Officer, succeeding Daniel Bensen.

Results of Operations and Financial Condition. On November 5, 2025, Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities…

Other Events. On August 21, 2025, Tyra Biosciences, Inc. (Tyra or the Company) announced the first child has been dosed in the BEACH301 Phase 2 clinical study of dabogratinib (formerly TYRA-300) in children with achondroplasia. The Company expects to report initial results from the safety sentinel cohort of the BEACH301 study in the second half of 2026. Forward-Looking Statements Tyra cautions you that statements contained in this report regarding matters that are not historical facts are for…

Results of Operations and Financial Condition. On August 14, 2025, Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Excha…

Other Events. On June 30, 2025, Tyra Biosciences, Inc. (Tyra or the Company) announced the first patient has been dosed in the SURF302 Phase 2 clinical study of TYRA-300 in low-grade, intermediate risk non-muscle invasive bladder cancer (IR NMIBC). SURF302 is an open-label Phase 2 clinical study evaluating the efficacy and safety of TYRA-300 in participants with FGFR3-altered low-grade, IR NMIBC. The study will enroll up to 90 participants at multiple sites primarily in the United States. Par…

Results of Operations and Financial Condition. On May 8, 2025, Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange…

Results of Operations and Financial Condition. On March 27, 2025, Tyra Biosciences, Inc. issued a press release announcing its financial results for the year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Excha…

Director — Nina Kjellson: Nina Kjellson resigned from the Board and was replaced by Adele M. Gulfo.

Results of Operations and Financial Condition. On November 7, 2024, Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities…

Other Events. On October 28, 2024, Tyra Biosciences, Inc. announced that the U.S. Food and Drug Administration (FDA) allowed the company’s Investigational New Drug (IND) application for TYRA-300 to proceed with a Phase 2 clinical trial of TYRA-300 for children with achondroplasia (BEACH301). BEACH301 will be a Phase 2, multicenter, open-label, dose-escalation/dose-expansion study evaluating TYRA-300 in children ages 3 to 10 with achondroplasia with open growth plates. The study will enroll ch…

Other Events. On October 24, 2024, the Company announced interim clinical proof-of-concept data for TYRA-300 in patients with mUC from its ongoing SURF301 Phase 1/2 study. As of August 15, 2024, the data cutoff date, 41 patients were enrolled in the Phase 1 portion of the SURF301 Phase 1/2 study. Eligible participants were adults with advanced malignancies with or without FGFR3 alterations, including those with prior treatment with erdafitinib. The enrolled patient population was heavily pre-…

Director — Siddarth Subramony, Ph.D.: Dr. Subramony resigned from the Board of Directors and the Compensation Committee.

Unregistered Sales of Equity Securities. On October 18, 2024, Tyra Biosciences, Inc. (the Company) entered into an exchange agreement with Boxer Capital, LLC (Boxer Capital) and RA Capital Healthcare Fund, L.P. (RA Capital) (each a Holder and collectively the Holders), pursuant to which (i) Boxer Capital agreed to exchange 2,000,000 shares of the Company’s common stock, par value $0.0001 per share (Common Stock), for one or more pre-funded warrants to acquire an aggregate of 2,000,000 shares…

Results of Operations and Financial Condition. On August 7, 2024, Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchan…

Material Modification to Rights of Security Holders. To the extent required by

Results of Operations and Financial Condition. On May 9, 2024, Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange…

Director — Isan Chen, M.D.: Dr. Isan Chen resigned from the Board and Compensation Committee.

Results of Operations and Financial Condition. On March 19, 2024, Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2023. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of t…

Entry into a Material Definitive Agreement On February 1, 2024, Tyra Biosciences, Inc. (the Company) entered into a securities purchase agreement (the Purchase Agreement) with the purchasers named therein (the Purchasers), for the private placement (the Private Placement) of (i) 9,286,023 shares (the Shares) of the Company’s common stock, par value $0.0001 per share (the Common Stock), at a price of $13.01 per Share, and (ii) with respect to certain Purchasers, pre-funded warrants to purchase…